Health Care • Biotechnology: Pharmaceutical Preparations
$2.54 ▼ -0.02
(-0.78%)
MKT CAP: $500.0M • VOL: 3.15M
52W L $1 52W H $3
OVID // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $7.3M | $566.0K | $392.0K |
| YoY Revenue Growth % | +1181.3% | +44.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.4M | -$61.9M | -$59.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$17.4M | -$26.4M | -$52.3M |
| EBITDA (Normalized) | -$42.4M | -$61.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$38.3M | -$56.0M | -$45.8M |
| Capital Expenditures (CapEx) | $0 | $71.0K | — |
| Free Cash Flow (FCF) | -$38.3M | -$56.0M | -$45.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -28.5% | -45.0% | — |
| Cash & Short-Term Equivalents | $13.2M | $26.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $130.7M | $68.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OVID.